


PHARMACEUTICAL 2019

ADIAL PHARMACEUTICALS INC. Rank 360 of 371







PHARMACEUTICAL 2019

ADIAL PHARMACEUTICALS INC. Rank 360 of 371

The relative strengths and weaknesses of ADIAL PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ADIAL PHARMACEUTICALS INC. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 446% points. The greatest weakness of ADIAL PHARMACEUTICALS INC. is the variable Net Income, reducing the Economic Capital Ratio by 1,052% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,708%, being 1,377% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	4,693
Cost of Goods Sold	0
Intangible Assets	6.7
Liabilities, Current	258
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-4,644
Property and Equipment	0
Research and Development	368
Revenues	0
Selling, General and Administrative Expense	6,619

Output Variable	Value in 1000 USD
Assets	4,699
Liabilities	258
Expenses	6,987
Stockholders Equity	4,441
Net Income	-11,631
Comprehensive Net Income	-11,631
Economic Capital Ratio	-1,708%

